Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

Fischer, 2019, Venetoclax and obinutuzumab in patients with CLL and coexisting conditions, N Engl J Med, 380, 2225, 10.1056/NEJMoa1815281 Al-Sawaf, 2020, Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 21, 1188, 10.1016/S1470-2045(20)30443-5 Deng, 2017, Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia, Leukemia, 31, 2075, 10.1038/leu.2017.32 Cervantes-Gomez, 2015, Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia, Clin Cancer Res, 21, 3705, 10.1158/1078-0432.CCR-14-2809 Hillmen, 2019, Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study, J Clin Oncol, 37, 2722, 10.1200/JCO.19.00894 Jain, 2019, Ibrutinib and venetoclax for first-line treatment of CLL, N Engl J Med, 380, 2095, 10.1056/NEJMoa1900574 Rogers, 2020, Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia, J Clin Oncol, 38, 3626, 10.1200/JCO.20.00491 Tam, 2020, A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study, Blood, 136, 2038, 10.1182/blood.2020006844 Flinsenberg, 2020, Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma, Haematologica, 105, e76, 10.3324/haematol.2019.220590 Tam, 2019, Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial, Blood, 134, 499, 10.1182/blood-2019-125394 Tam, 2019, Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL, Blood, 134, 851, 10.1182/blood.2019001160 Swerdlow, 2017 Hallek, 2018, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, 131, 2745, 10.1182/blood-2017-09-806398 2017 A'Hern, 2001, Sample size tables for exact single-stage phase II designs, Stat Med, 20, 859, 10.1002/sim.721 2016, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, 17, 779, 10.1016/S1470-2045(16)30029-8 Wierda, 2020, Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study, Blood, 123, 16, 10.1182/blood-2020-134446 Davids, 2020, Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL), Blood, 136, 20, 10.1182/blood-2020-139864 Rawstron, 2013, Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL, Leukemia, 27, 142, 10.1038/leu.2012.216 Sharman, 2020, Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial, Lancet, 395, 1278, 10.1016/S0140-6736(20)30262-2 Shanafelt, 2019, Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia, N Engl J Med, 381, 432, 10.1056/NEJMoa1817073 Woyach, 2018, Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL, N Engl J Med, 379, 2517, 10.1056/NEJMoa1812836 Gregory, 2020, Extrapolating progression free survival curves in CLL using peripheral blood MRD measurements from venetoclax trials, HemaSphere, 4 Hillmen, 2020, Continued long term responses to ibrutinib + venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP clarity trial, Blood, 136, 17, 10.1182/blood-2020-136960 Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519 Seymour, 2017, Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study, Lancet Oncol, 18, 230, 10.1016/S1470-2045(17)30012-8 Seymour, 2018, Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia, N Engl J Med, 378, 1107, 10.1056/NEJMoa1713976 Kater, 2019, Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study, J Clin Oncol, 37, 269, 10.1200/JCO.18.01580